Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Buclizine→

Buclizine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
82-95-1
Molecular formula
C28H33ClN2
Molecular weight
433 g/mol
Drug class
First-generation piperazine antihistamineH1 receptor antagonist with antiemetic effects
Mechanism of action
Antagonises central and peripheral histamine H1 receptors and has anticholinergic activity, reducing vestibular stimulation and emetic signalling.
Indications / reported uses
  • Prevention and symptomatic treatment of nausea, vomiting and motion sickness in countries where buclizine products are authorised; product-specific age and route restrictions apply

Sources: NLM MeSH — Buclizine · PubMed — Buclizine antihistamine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Buclizine Environmental Risk Assessment (ERA) (the Buclizine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.